Compare PTGX & CE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | CE |
|---|---|---|
| Founded | 2006 | 1918 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.3B |
| IPO Year | 2016 | 2005 |
| Metric | PTGX | CE |
|---|---|---|
| Price | $82.47 | $46.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | ★ $93.00 | $55.82 |
| AVG Volume (30 Days) | 788.9K | ★ 2.0M |
| Earning Date | 02-20-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 0.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $9,710,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $409.41 | $0.14 |
| P/E Ratio | $115.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.70 | $35.13 |
| 52 Week High | $96.54 | $75.84 |
| Indicator | PTGX | CE |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 55.50 |
| Support Level | $81.94 | $43.73 |
| Resistance Level | $85.50 | $48.06 |
| Average True Range (ATR) | 3.16 | 1.99 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 40.39 | 63.00 |
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.